MedTrace Logo

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00053105 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-07-07

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Conditions

Interventions

DRUG

cisplatin

DRUG

cytarabine

DRUG

methylprednisolone

DRUG

pixantrone dimaleate

Sponsors & Collaborators

  • Theradex

    lead INDUSTRY

Principal Investigators

  • Luis Fayad, MD · M.D. Anderson Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00053105 on ClinicalTrials.gov